Longeveron

LGVN

Biotechnology · Healthcare

Exchange

NASDAQ Capital Market

Winston Score

Winston is worried

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Mixed

Growth

Mixed

Cash Flow

Weak

Stability

Data not available

Valuation

Data not available

Track this stock — start free trial

Winston Score History

The full picture

Longeveron is a small clinical-stage biotechnology company focused on developing cell therapies to treat aging-related and life-threatening diseases. Its lead product, Lomecel-B, is made from special cells called medicinal signaling cells (MSCs) sourced from the bone marrow of healthy young donors. The company is targeting conditions like Alzheimer's disease, aging frailty, and hypoplastic left heart syndrome, a serious heart defect in children.

Longeveron earns very little revenue today, as its therapies are still in clinical trials and not yet approved for commercial sale. It is based in Miami, Florida, and operates primarily in the United States. The company burns significantly more cash than it brings in, which is typical for early-stage biotech firms but creates real risk — it must keep raising money to fund research. The biggest near-term driver is whether clinical trial results for Lomecel-B are strong enough to support regulatory approval, which would be required before any meaningful revenue can be generated.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-9.2% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+42.4% YoY

YoY Growth Rate

Strong earnings growth

Insider Activity

18.3%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~5 months

$10M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Cash watch

Longeveron has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

63.4%

Premium pricing power — 63.4% gross margin

Profit after running costs

Operating Margin

-2150.2%

Losing money on operations — -2150.2%

Return on the money invested

ROCE

-227.4%

Weak — -227.4% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-42.7%

Shrinking sales (-42.7% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

7/8 quarters

Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-1742.1%

Burning cash (-1742.1%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial